M&G UK Income Distribution Fund Sterling R Inc (0P0000WN2T)

Overview

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to creating innovative treatments for various viral and liver diseases, addressing significant unmet medical needs. With a strong focus on research and development, the company is pioneering in the discovery of novel therapeutics. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California, positioning itself at the forefront of biotechnological advancements. Through its strategic collaborations with leading institutions and companies, Aligos is advancing its mission to deliver transformative medicines to patients worldwide.

Products and Services

Listed below are the key drug candidates and programs currently being developed by Aligos Therapeutics, Inc.:

• ALG-055009: A small molecule THR-ß agonist currently in the Phase 2a clinical trial stages for treating non-alcoholic steatohepatitis (NASH), ALG-055009 represents Aligos's commitment to addressing liver diseases with significant unmet medical needs.
• ALG-000184: This capsid assembly modulator has completed Phase 1b clinical trials for the treatment of chronic hepatitis B (CHB), showcasing Aligos's efforts to innovate in combating viral diseases more effectively.
• ALG-125755: A siRNA (small interfering RNA) drug candidate in Phase I clinical trial aimed at treating chronic hepatitis B (CHB). This demonstrates Aligos's expertise in RNA-based therapies and its potential to disrupt viral replication mechanisms.
• ALG-097558: Currently in Phase 2 clinical trials, this drug candidate is being developed for the treatment of coronavirus, highlighting Aligos’s rapid response to emergent global health threats.

Aligos Therapeutics, Inc. has engaged in several key collaborations to accelerate its drug development processes and expand its therapeutic reach:

• A license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a target for NASH.
• A license agreement with Emory University, providing Aligos access to cutting-edge hepatitis B virus capsid assembly modulator technology.
• A development and commercialization partnership with Luxna Biotech Co., Ltd., aimed at bringing forth products containing oligonucleotides targeting the hepatitis B virus genome.
• A research, licensing, and commercialization agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, amplifying Aligos's portfolio in antiviral research.
• A clinical collaboration with Xiamen Amoytop Biotech Co., Ltd., further underscores the global outreach and cooperative strategy Aligos applies to its research and development endeavors.